Business Wire

Results from Blue Earth Diagnostics’ LOCATE Trial Show 59% of Patients with Suspected Recurrent Prostate Cancer Had Change in Management Plan Following

BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced the topline results from an investigational clinical trial ...
EurekAlert!

Imaging tool helps locate recurrent prostate cancer

DURHAM, N.C. -- A new multi-institutional study led by investigators at Duke University Medical Center indicates that a diagnostic scan may help localize recurrent prostate disease in men who have had ...
Business Wire

Blue Earth Diagnostics Announces Results of Additional Analyses from LOCATE Trial Evaluating Change in Recurrent Prostate Cancer Management Following Axumin ® (Fluciclovine F ...

The LOCATE trial was a prospective, U.S., multicenter, open-label study investigating the impact of 18 F-fluciclovine PET/CT imaging on patient management of biochemically recurrent prostate cancer ...
EurekAlert!

UCLA researchers locate and image prostate cancer as it spreads to lymph nodes

Using an engineered common cold virus, UCLA researchers delivered a genetic payload to prostate cancer cells that allowed them, using Positron Emission Tomography (PET), to locate the diseased cells ...